Overexpression of XRCC1 is Associated with Poor Survival in Patients with Head and Neck Squamous Carcinoma and Has Potential to Be Used as Targeted Therapy by Synthetic Lethality.

These results indicate that XRCC1 is a prognostic marker for predicting survival in HNSCC patients. Understanding how XRCC1 leads to treatment resistance and modulate immune response can lead to development of targeted therapy.